Advertisement

Ex vivo gene transferring of human dimethylarginine dimethylaminohydrolase-2 improved endothelial dysfunction in diabetic rat aortas and high glucose-treated endothelial cells

      Abstract

      Objectives

      Elevated level of asymmetric dimethylarginine (ADMA) is an independent risk factor for endothelial dysfunction. Dimethylarginine dimethylaminohydrolase (DDAH) is the key enzyme responsible for the degradation of endogenous ADMA. The purposes of this study were to determine whether suppressed DDAH2 expression would implicate in endothelial dysfunction associated with diabetes mellitus and further to investigate whether adenovirus-mediated DDAH2 gene overexpression could improve the hyperglycemia-induced endothelial dysfunction.

      Methods

      Diabetic model was induced by intraperitoneal injection of streptozotocin to male Sprague–Dawley rats. Recombinant adenoviral vector encoding human DDAH2 gene driven by a cytomegalovirus promoter was constructed to overexpress hDDAH2 gene in isolated rat aortas and endothelial cells. Changes in DDHA/ADMA/nitric oxide (NO) pathway in diabetic rats and high glucose-treated endothelial cells were examined.

      Results

      DDAH2 expression was distinctly suppressed, which was accompanied by inhibited DDAH activity and impaired endothelium-dependent relaxation in aortas, and elevated ADMA concentrations in serum of diabetic rats compared to control rats. Suppressions of DDAH2 expression and DDAH activity, accumulation of ADMA, and inhibition of NO synthesis were observed in high glucose-treated endothelial cells. DDAH2 overexpression not only improved endothelial dysfunction in diabetic aortas but also attenuated hyperglycemia-induced changes in DDAH/ADMA//NO pathway in endothelial cells.

      Conclusion

      These results indicate that suppression of DDAH2 expression contributes to hyperglycemia-induced endothelial dysfunction, which can be improved by DDAH2 overexpression. This study suggests that targeted modulation of DDAH2 gene in vascular endothelium may be a novel approach for the treatment of endothelial dysfunction in diabetes mellitus.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wild S.
        • Roglic G.
        • Green A.
        • Sicree R.
        • King H.
        Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.
        Diabetes Care. 2004; 27: 1047-1053
        • Farhangkhoee H.
        • Khan Z.A.
        • Kaur H.
        • et al.
        Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets.
        Pharmacol Ther. 2006; 111: 384-399
        • Cooke J.P.
        • Tsao P.S.
        Arginine: a new therapy for atherosclerosis?.
        Circulation. 1997; 95: 311-312
        • Xiong Y.
        • Lu R.
        • Li Y.J.
        • Deng H.W.
        Elevation of an endogenous inhibitor of nitric oxide synthase in diabetic rat serum.
        Zhongguo Yao Li Xue Bao. 1997; 18: 511-514
        • Lin K.Y.
        • Ito A.
        • Asagami T.
        • et al.
        Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.
        Circulation. 2002; 106: 987-992
        • Masuda H.
        • Goto M.
        • Tamaoki S.
        • Azuma H.
        Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia.
        Br J Pharmacol. 1999; 126: 211-218
        • Stuhlinger M.C.
        • Abbasi F.
        • Chu J.W.
        • et al.
        Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.
        JAMA. 2002; 287: 1420-1426
        • Fard A.
        • Tuck C.H.
        • Donis J.A.
        • et al.
        Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes.
        Arterioscler Thromb Vasc Biol. 2000; 20: 2039-2044
        • Xiong Y.
        • Fu Y.F.
        • Fu S.H.
        • Zhou H.H.
        Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocin-induced diabetes.
        J Cardiovasc Pharmacol. 2003; 42: 191-196
        • Xiong Y.
        • Lei M.
        • Fu S.
        • Fu Y.
        Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes.
        Life Sci. 2005; 77: 149-159
        • Boisvert F.M.
        • Cote J.
        • Boulanger M.C.
        • Richard S.
        A proteomic analysis of arginine-methylated protein complexes.
        Mol Cell Proteomics. 2003; 2: 1319-1330
        • MacAllister R.J.
        • Parry H.
        • Kimoto M.
        • et al.
        Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase.
        Br J Pharmacol. 1996; 119: 1533-1540
        • Leiper J.M.
        • Santa Maria J.
        • Chubb A.
        • et al.
        Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases.
        Biochem J. 1999; 343: 209-214
        • Ito A.
        • Tsao P.S.
        • Adimoolam S.
        • et al.
        Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase.
        Circulation. 1999; 99: 3092-3095
        • Stuhlinger M.C.
        • Tsao P.S.
        • Her J.H.
        • et al.
        Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine.
        Circulation. 2001; 104: 2569-2575
        • Fu Y.F.
        • Xiong Y.
        • Guo Z.
        A reduction of endogenous asymmetric dimethylarginine contributes to the effect of captopril on endothelial dysfunction induced by homocysteine in rats.
        Eur J Pharmacol. 2005; 508: 167-175
        • Yin Q.F.
        • Fu S.H.
        • He P.
        • Xiong Y.
        Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein: effects of aminoguanidine.
        Atherosclerosis. 2007; 190: 53-61
        • Xiong Y.
        • Collins Q.F.
        • An J.
        • et al.
        p38 mitogen-activated protein kinase plays an inhibitory role in hepatic lipogenesis.
        J Biol Chem. 2007; 282: 4975-4982
        • Lu C.W.
        • Xiong Y.
        • He P.
        Dimethylarginine dimethylaminohydrolase-2 overexpression improves impaired nitric oxide synthesis of endothelial cells induced by glycated protein.
        Nitric Oxide. 2007; 16: 94-103
        • Monsalve E.
        • Oviedo P.J.
        • Garcia-Perez M.A.
        • et al.
        Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human endothelial cells.
        Cardiovasc Res. 2007; 73: 66-72
        • Dayal S.
        • Rodionov R.N.
        • Arning E.
        • et al.
        Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia.
        Am J Physiol Heart Circ Physiol. 2008; 295: H816-H825
        • Sorrenti V.
        • Mazza F.
        • Campisi A.
        • et al.
        High glucose-mediated imbalance of nitric oxide synthase and dimethylarginine dimethylaminohydrolase expression in endothelial cells.
        Curr Neurovasc Res. 2006; 3: 49-54
        • Chen Y.
        • Park S.
        • Li Y.
        • et al.
        Alterations of gene expression in failing myocardium following left ventricular assist device support.
        Physiol Genomics. 2003; 14: 251-260
        • Wakino S.
        • Hayashi K.
        • Tatematsu S.
        • et al.
        Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats.
        Hypertens Res. 2005; 28: 255-262
        • Wang D.
        • Gill P.S.
        • Chabrashvili T.
        • et al.
        Isoform-specific regulation by N(G),N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO.
        Circ Res. 2007; 101: 627-635
        • Hasegawa K.
        • Wakino S.
        • Tatematsu S.
        • et al.
        Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2.
        Circ Res. 2007; 101: e2-10
        • Achan V.
        • Tran C.T.
        • Arrigoni F.
        • et al.
        all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase.
        Circ Res. 2002; 90: 764-769
        • Pullamsetti S.
        • Kiss L.
        • Ghofrani H.A.
        • et al.
        Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension.
        FASEB J. 2005; 19: 1175-1177
        • Noyman I.
        • Marikovsky M.
        • Sasson S.
        • et al.
        Hyperglycemia reduces nitric oxide synthase and glycogen synthase activity in endothelial cells.
        Nitric Oxide. 2002; 7: 187-193